Stroke research and treatment · 2026
Real-World Evidence Assessment of the Risk of Nonfatal Stroke in Patients Prescribed SGLT2 Inhibitors.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ayers Alessandra T, Ho Cindy N, Masharani Umesh, Pike William C, Magon Honor, Jackson Michael L, Gombar Saurabh, Scheideman Agatha F, Shao Mandy M, Klonoff David C
Аннотация
AIMS: Use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adults with Type 2 diabetes (AwT2D) has recently been associated with decreased stroke risk. In this study, we investigate the impact of SGLT2i on stroke.
MATERIALS AND METHODS: We conducted a cohort study using an electronic health record (EHR) representing 66 million patients to examine whether AwT2D have a lower incidence of stroke and/or transient ischemic attack (TIA) if treated with SGLT2i. All analyses were completed utilizing high-dimensional propensity score matching to control for confounders.
RESULTS: AwT2D treated with SGLT2i compared to other antidiabetic medications, assessed after 1 year, starting 2 weeks after the date of prescription of SGLT2i or other antidiabetic drug, had a significantly lower incidence of any stroke (Odds Ratio (OR): 0.84 with 95% Confidence Interval (CI) 0.79-0.91, p < 0.001), hemorrhagic stroke (OR: 0.72 with 95% CI 0.59-0.88, p < 0.001), ischemic stroke (OR: 0.86 with 95% CI 0.77-0.95, p = 0.005), and TIA (OR: 0.87 with 95% CI 0.80-0.95, p = 0.003).
CONCLUSION: Among AwT2D, those treated with SGLT2i had lower incidence of stroke and TIA compared with adults treated with other antidiabetic medications.
MATERIALS AND METHODS: We conducted a cohort study using an electronic health record (EHR) representing 66 million patients to examine whether AwT2D have a lower incidence of stroke and/or transient ischemic attack (TIA) if treated with SGLT2i. All analyses were completed utilizing high-dimensional propensity score matching to control for confounders.
RESULTS: AwT2D treated with SGLT2i compared to other antidiabetic medications, assessed after 1 year, starting 2 weeks after the date of prescription of SGLT2i or other antidiabetic drug, had a significantly lower incidence of any stroke (Odds Ratio (OR): 0.84 with 95% Confidence Interval (CI) 0.79-0.91, p < 0.001), hemorrhagic stroke (OR: 0.72 with 95% CI 0.59-0.88, p < 0.001), ischemic stroke (OR: 0.86 with 95% CI 0.77-0.95, p = 0.005), and TIA (OR: 0.87 with 95% CI 0.80-0.95, p = 0.003).
CONCLUSION: Among AwT2D, those treated with SGLT2i had lower incidence of stroke and TIA compared with adults treated with other antidiabetic medications.